EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Eikon Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.70+0.28 (+3.77%)
Close on Oct 19, 2026
- Market cap
- $416.90M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | – | – | – |
Press releases
Announcements Eikon Therapeutics filed with the SEC
Q3 Company Update August 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Eikon Therapeutics Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Q2 Company Update June 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 Company Presentation May 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Results of operations · EX-99.1 to Form 8-K